Dr. Jeffrey Michael Melancon, MD, PhD

Dr. Melancon practices at Sharp Rees-Stealy Medical Group, Inc in San Diego, California.

Dr. Melancon's NPI, 1508007568, was assigned on March 20, 2009. Dr. Melancon graduated from LSU Health Sciences Center New Orleans - School of Medicine in 2009. Dr. Melancon holds California license A114879.

Dr. Melancon's primary practice is Sharp Rees-Stealy Medical Group, Inc, at 5651 Copley Dr, San Diego, CA 92111 in San Diego County. The practice phone is (858) 262-6666.

Dr. Melancon's primary practice is Sharp Rees-Stealy Medical Group, Inc in San Diego, California. The medical group on file is Sharp Rees-Stealy Medical Group. Dmand AI also links Dr. Melancon to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melancon practices. Vendor and product names are available with a free account.

Dermatology is Dr. Melancon's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Melancon is board certified in dermatology by the American Board of Dermatology. Dr. Melancon is licensed in California.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, itchy rashes, psoriasis, scalp rash, skin cyst and skin discoloration among the conditions Dr. Melancon treats.

CMS data shows 2,566 Medicare services from Dr. Melancon across 15 procedure codes in 2024, for 392 Medicare patients. Medicare paid $118,668 for them. Every service was in an office.

CMS counts 392 Medicare patients who saw Dr. Melancon in 2024. The largest group is 65 to 74, with 216 patients. 58% of them have high cholesterol, and 52% have high blood pressure. 5% are also on Medicaid. Their average risk score is 0.82, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Melancon's median patient age at 67, with 43% women.

In 2024, Dr. Melancon wrote 965 Medicare Part D claims for 379 patients. 93% of them were for generic drugs. CMS names the drug for 847 of them, across 18 drugs with 11 or more claims each, at $306,312 in total drug cost. In 2023, CMS named 829 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Melancon for performance year 2024, reported as part of a group. Dr. Melancon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Melancon as offering telehealth. CMS counts 108 procedures of melanoma (skin cancer) excision by Dr. Melancon, more than 94% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Melancon, published from 2005 to 2007. 2007 was the busiest year, with 2. The most frequent topics are Chlorocebus aethiops, Herpesvirus 1, Human and Vero Cells. Dr. Melancon has published most often in J Virol. Dr. Melancon's most frequent co-authors are Carter Thomas Davis, MD, Magdalene Annette Dohil, MD and Kian Ehsan, MD.

CMS Open Payments shows 83 general payments to Dr. Melancon from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 58% of the total. Pfizer Inc. paid the most, $1,515.

Dr. Melancon graduated from LSU Health Sciences Center New Orleans - School of Medicine in 2009.

Dr. Melancon is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.